> Research Use Only Disclaimer: SNAP-8 (Acetyl Octapeptide-3) is a cosmetic research peptide not approved by the FDA as a therapeutic drug. All dosage information, formulation protocols, and data presented in this article are sourced from peer-reviewed scientific literature, cosmetic clinical studies, and manufacturer specifications. This content is for educational and research purposes only and does not constitute medical advice. Do not administer SNAP-8 or any research peptide to humans outside of an approved clinical research protocol.
SNAP-8 is among the most commercially significant anti-aging research peptides, with 48 supplier listings on Peptides.SO making it one of the most widely stocked cosmetic peptides on the platform. Despite its broad availability, standardized concentration protocols and vehicle formulation guidance for research applications remain fragmented across technical literature.
This guide consolidates published reconstitution data, cosmetic research trial protocols, and in vitro keratinocyte study parameters to support researchers and formulators working with SNAP-8.
---
What Is SNAP-8? SNARE Complex Inhibition Overview
SNAP-8 (also designated Acetyl Octapeptide-3, INCI name: Acetyl Octapeptide-3) is a synthetic acetylated octapeptide derived from the N-terminal domain of synaptosomal-associated protein 25 (SNAP-25). Its sequence — Ac-EEMQRRAD-NH₂ — mimics the SNAP-25 segment that participates in SNARE complex assembly at the neuromuscular junction.
Molecular characteristics:
- •Molecular weight: 1,075.16 Da
- •Sequence: Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂ (8 amino acids)
- •Form: Synthetic peptide, white to off-white lyophilized powder
- •Net charge at physiological pH: Approximately −1 to −2 (anionic character from glutamic and aspartic acid residues)
- •Water solubility: High (>50 mg/mL in aqueous buffers)
Mechanism: Competitive SNARE Disruption
SNAP-25 is an essential component of the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptor) complex that mediates vesicle fusion at the neuromuscular junction. During normal transmission, the SNARE complex assembles between syntaxin, synaptobrevin (VAMP), and SNAP-25 to drive acetylcholine release — triggering muscle contraction and, at the facial level, expression line formation.
SNAP-8 competitively disrupts this process:
1. Competitive binding — SNAP-8's sequence mimics the SNAP-25 N-terminal domain and competes with endogenous SNAP-25 for SNARE complex assembly
2. Reduced vesicle fusion efficiency — Partial SNARE complex inhibition reduces the probability of acetylcholine exocytosis per nerve impulse
3. Attenuated muscle contraction — Lower acetylcholine release dampens the magnitude (but does not abolish) contraction at target muscles
4. Wrinkle depth reduction — Reduced contraction frequency and intensity over time attenuates dynamic line deepening in cosmetic research models
This mechanism is often described as a "topical alternative" to botulinum toxin A, though the mechanism of action differs fundamentally: botulinum toxin cleaves SNARE proteins enzymatically; SNAP-8 works through competitive peptide inhibition at substantially lower potency and with complete reversibility.
Comparison with Related Peptides
| Feature | SNAP-8 (Acetyl Octapeptide-3) | Argireline (Acetyl Hexapeptide-3) | Botulinum Toxin A |
|---|---|---|---|
| Peptide length | 8 residues | 6 residues | Protein (~150 kDa) |
| MW | 1,075 Da | 889 Da | ~150,000 Da |
| Mechanism | SNARE competitive inhibition | SNARE competitive inhibition | SNARE proteolytic cleavage |
| Topical penetration | Enhanced vs. hexapeptide | Moderate | None (requires injection) |
| Reversibility | Fully reversible | Fully reversible | Semi-permanent (months) |
| Research context | Cosmetic/topical | Cosmetic/topical | Clinical therapeutic |
---
Research Forms and Preparations
Lyophilized Powder Specifications
SNAP-8 for cosmetic and research use is supplied as lyophilized white powder with the following standard specifications:
| Specification | Research Grade | Cosmetic Grade |
|---|---|---|
| Purity | ≥95% (HPLC) | ≥98% (HPLC) |
| Appearance | White to off-white powder | White powder |
| Molecular weight | 1,075.16 Da (confirmed by MS) | 1,075.16 Da (confirmed by MS) |
| Solubility | >50 mg/mL in water | >50 mg/mL in water |
| Shelf life (lyophilized, −20°C) | 24+ months | 24+ months |
| Counter-ion | Acetate | Acetate |
Pre-Formulated Liquid Concentrates
Many cosmetic ingredient suppliers offer SNAP-8 as pre-dissolved liquid concentrates (typically 5–10% w/v in aqueous solution or propylene glycol/water mixture). These are ready-to-incorporate into finished formulations without reconstitution:
- •10% aqueous solution: Most common commercial form; directly incorporate at 3–10% of finished formulation weight to achieve 0.3–1.0% active
- •5% solution in PG/water: Provides humectant co-solvent benefits; slightly lower required volume for equivalent dosing
---
Reconstitution Protocol (Lyophilized Powder)
Recommended Solvent: Sterile Water or Aqueous Buffer
SNAP-8's high water solubility and predominantly anionic character make it among the easiest cosmetic peptides to reconstitute. Unlike cationic peptides prone to aggregation at neutral pH, SNAP-8 dissolves readily in:
Primary solvents:
- •Sterile distilled water (pH 6.0–7.0): Preferred for maximum solubility
- •Phosphate buffered saline (PBS, pH 7.4): For cell culture work
- •1,3-Butylene glycol or propylene glycol (10–30%): For cosmetic vehicle preparation
Secondary options (for emulsion incorporation):
- •Glycerin/water mixture (20:80): Provides humectant synergy in topical formulations
- •DMSO (for permeation enhancement studies): Use at <2% v/v final concentration
Avoid:
- •High-pH buffers (>pH 8.5): Risk of asparagine deamidation
- •Prolonged exposure to oxidizing agents: Methionine (Met₃) is susceptible to oxidation; use antioxidants (vitamin E, ferulic acid) in cosmetic formulations
Step-by-Step Reconstitution (Research Grade)
| Step | Action | Notes |
|---|---|---|
| 1 | Equilibrate lyophilized vial to room temperature | Prevents condensation contamination |
| 2 | Add sterile water to achieve target concentration | 1–10 mg/mL stock range typical |
| 3 | Gently swirl or invert 10–20× | Do not vortex — unnecessary agitation |
| 4 | Allow 2–5 minutes for complete dissolution | Solution should be clear and colorless |
| 5 | Check pH (target 5.5–7.0 for cosmetic use) | Adjust with citric acid/NaOH if needed |
| 6 | Aliquot for single-use or short-term storage | Minimize freeze-thaw cycles |
Concentration Reference Table
| SNAP-8 Powder | Solvent Volume | Resulting Concentration |
|---|---|---|
| 1 mg | 0.1 mL sterile water | 10 mg/mL (10,000 µg/mL) |
| 1 mg | 0.2 mL sterile water | 5 mg/mL (5,000 µg/mL) |
| 1 mg | 1 mL sterile water | 1 mg/mL (1,000 µg/mL) |
| 5 mg | 0.5 mL sterile water | 10 mg/mL (stock) |
| 50 mg | 5 mL sterile water | 10 mg/mL (bulk stock) |
Working dilutions for cosmetic formulations: Dilute stock into the aqueous phase of emulsions at temperatures below 40°C to preserve peptide integrity.
---
Research Dosing Ranges: What the Literature Reports
Topical Cosmetic Research Concentrations
SNAP-8 research in published cosmetic studies uses concentration as the primary dosing parameter (rather than systemic mg/kg). Published trials and formulation data consistently use the following concentration ranges:
| Application Context | Concentration Range | Formulation Type | Notes |
|---|---|---|---|
| Proof-of-concept ex vivo | 0.5–1% w/w | Simple aqueous gel | Confirms peptide stability in matrix |
| Clinical wrinkle reduction trials | 3% w/w | Emulsion or serum | Most commonly studied concentration |
| Enhanced efficacy formulations | 5–10% w/w | Serum/active concentrate | High-dose cosmetic research |
| Comparative SNAP-8 vs. Argireline | 3% each | Matched formulations | Direct head-to-head published data |
| Penetration enhancement studies | 1–3% w/w + enhancers | DMSO, liposomes, nanocarriers | Permeation focus studies |
The 3% concentration landmark: Multiple published studies use 3% SNAP-8 as the reference concentration. A key study by Blanes-Mira et al. (published in the International Journal of Cosmetic Science) using in vitro catecholamine release assays demonstrated that SNAP-8 at 3% produced statistically significant inhibition of SNARE-mediated vesicle exocytosis and was 30% more effective than Argireline (Acetyl Hexapeptide-3) at equivalent concentrations.
In Vitro Keratinocyte and Neuroendocrine Research Models
For cell-based research examining SNARE inhibition mechanisms:
| Model | Concentration Range | Endpoint | Published Data |
|---|---|---|---|
| PC12 catecholamine release assay | 0.001–1 mg/mL | Inhibition of exocytosis % | Blanes-Mira et al., 2002 |
| HaCaT keratinocyte viability | 0.1–10 mg/mL | MTT / Live-Dead assay | Establishes cytotoxicity threshold |
| Skin explant contraction model | 1–5% topical | Muscle contraction frequency | Ex vivo facial skin assay |
| Dermal fibroblast migration | 0.01–0.1 mg/mL | Scratch wound assay | Secondary wound-adjacent research |
| Primary neuromuscular junction model | 10–100 µg/mL | ACh release inhibition % | Electrophysiological assay |
Cytotoxicity threshold: Published data suggest SNAP-8 at concentrations ≤5 mg/mL is non-cytotoxic to primary keratinocytes and HaCaT cells. Concentrations above 10 mg/mL in direct cell culture may reduce viability, though this is not a relevant concern at cosmetic use levels (3–10% in formulation = far lower actual peptide contact concentration at cell surfaces).
Published Clinical Data Summary
Blanes-Mira et al. (2002) — Foundational SNAP-8 Study:
- •Model: PC12 cells (dopaminergic neuroendocrine model)
- •Concentrations tested: 10⁻³ to 1 mg/mL
- •Finding: SNAP-8 inhibited KCl-induced catecholamine secretion in a dose-dependent manner; IC₅₀ approximately 0.1 mg/mL
- •Comparison: 30% greater inhibitory effect vs. Acetyl Hexapeptide-3 at matched concentrations
- •Significance: Established the mechanistic basis for SNAP-8 topical claims
Cosmetic Clinical Study Data (supplier-reported, peer-reviewed protocols):
- •Study design: 30-day randomized application, 2× daily, 3% SNAP-8 vs. placebo emulsion
- •Participants: Volunteers aged 37–60 years with periorbital expression lines
- •Primary endpoint: Wrinkle depth reduction (optical profilometry)
- •Reported outcome: 26.5% reduction in wrinkle volume; 16.5% reduction in wrinkle depth at day 28 versus placebo baseline
- •Adverse events: None reported; confirmed non-irritant under repeat insult patch test
---
Formulation Protocols for Research Applications
Standard Research Emulsion (3% SNAP-8)
For reproducible research formulations at the commonly studied 3% concentration:
| Phase | Ingredient | % w/w | Function |
|---|---|---|---|
| Water phase | Purified water | 74.0% | Base |
| Water phase | Glycerin | 5.0% | Humectant |
| Water phase | Sodium hyaluronate (HMW) | 0.5% | Film former |
| Oil phase | Cetearyl alcohol | 3.0% | Emulsifier |
| Oil phase | Caprylic/capric triglyceride | 8.0% | Emollient |
| Oil phase | Dimethicone | 2.0% | Skin feel |
| Preservative | Phenoxyethanol (≤1%) | 1.0% | Preservation |
| Active — add-in | SNAP-8 (from 10% solution) | 3.0% | Active ingredient |
| Adjust | Citric acid/NaOH | q.s. | pH 5.5–6.0 |
Processing notes:
1. Heat water and oil phases separately to 75°C
2. Combine oil-into-water with homogenization (3,000–5,000 RPM, 3 minutes)
3. Cool under slow mixing to below 40°C
4. Add SNAP-8 concentrate at ≤40°C with gentle mixing
5. Adjust pH; fill
Serum-Type Formulation (5% SNAP-8)
For high-concentration serum research (higher active load):
| Phase | Ingredient | % w/w |
|---|---|---|
| Water phase | Purified water | 80.5% |
| Water phase | Glycerin | 3.0% |
| Water phase | Sodium hyaluronate (LMW) | 0.5% |
| Water phase | Panthenol | 1.0% |
| Thickener | Carbomer | 0.5% |
| Neutralizer | Triethanolamine | 0.5% |
| Active — add-in | SNAP-8 (from 10% solution) | 5.0% |
| Preservative | Ethylhexylglycerin/phenoxyethanol blend | 1.0% |
| Adjust | pH to 5.5–6.5 | q.s. |
---
Stability and Storage
Peptide Stability Profile
| Condition | Stability | Notes |
|---|---|---|
| Lyophilized, −20°C, dark | >24 months | Long-term storage; protect from moisture |
| Aqueous solution, 4°C | 6–12 months | Stable in acidic-neutral pH range |
| Aqueous solution, 25°C | 1–3 months | Use antioxidants; monitor pH drift |
| Formulated emulsion, 25°C | 3–6 months | Typical cosmetic product shelf life |
| Formulated emulsion, 40°C (accelerated) | 4–6 weeks | Stability chamber testing standard |
| Freeze-thaw cycling (stock solution) | ≤3 cycles recommended | Monitor by HPLC for degradation |
Key Degradation Pathways
Methionine oxidation (Met₃): The methionine at position 3 of the SNAP-8 sequence is susceptible to oxidation by peroxides, transition metals, and UV. Mitigation strategies:
- •Include antioxidants in formulations (vitamin E acetate 0.1–0.5%, ascorbyl glucoside, ferulic acid)
- •Avoid metal-contaminated equipment; use stainless steel or glass
- •Keep pH ≤6.5 to minimize peroxide formation from autooxidation
Asparagine deamidation (Asn, if applicable): Minor risk at pH >7 and elevated temperatures. Maintaining formulation pH 5.5–6.5 substantially reduces this degradation pathway.
Concentration monitoring: For rigorous research applications, confirm active concentration at batch completion by reverse-phase HPLC against authenticated SNAP-8 reference standard.
---
Combination Research Protocols
SNAP-8 + Argireline Stack (Dual SNARE Inhibition)
Several published formulation studies combine SNAP-8 with Argireline (Acetyl Hexapeptide-3) for potentially additive SNARE inhibition:
| Formulation Component | Concentration | Rationale |
|---|---|---|
| SNAP-8 (Acetyl Octapeptide-3) | 3% w/w | Primary SNARE inhibitor; broader binding domain |
| Argireline (Acetyl Hexapeptide-3) | 5% w/w | Complementary SNARE inhibition; different subunit targeting |
Research rationale: SNAP-8 targets the full SNAP-25 N-terminal binding region (8-mer); Argireline (6-mer, subset sequence) targets a shorter domain. Combination may produce complementary SNARE complex disruption. Published data suggest additive, not synergistic, effects at these concentrations.
SNAP-8 + Penetration Enhancers
Topical peptide penetration through the stratum corneum is a key challenge. Research protocols using penetration enhancement:
| Enhancer | Concentration | Mechanism | SNAP-8 Penetration Impact |
|---|---|---|---|
| Dimethyl sulfoxide (DMSO) | 1–5% v/v | Solvent displacement | 2–4× increased penetration depth |
| Sodium lauroyl sarcosinate | 0.5–2% | Detergent disruption | Moderate increase |
| Liposomal encapsulation | 1:1–4:1 lipid:peptide ratio | Vesicular delivery | Sustained release at target site |
| Ethanol | 5–20% | Extraction facilitation | Concentration-dependent |
| Lipid nanoparticles (LNPs) | — | Carrier | Published in skin permeation models |
---
Quality Control for Research Applications
HPLC Purity Verification
For research-grade SNAP-8:
- •Method: Reverse-phase HPLC (C18 column, gradient elution with acetonitrile/water + 0.1% TFA)
- •Target purity: ≥95% for research use; ≥98% for comparative mechanistic studies
- •Retention time confirmation: Compare against authenticated SNAP-8 reference standard from certificate of analysis
Key QC Metrics
| QC Parameter | Acceptance Criterion | Test Method |
|---|---|---|
| Purity | ≥95% (research) / ≥98% (high grade) | RP-HPLC |
| Molecular weight | 1,075.16 ± 0.5 Da | Mass spectrometry (ESI-MS) |
| Appearance | White to off-white powder | Visual |
| Moisture content | <8% | Karl Fischer titration |
| Endotoxin (for cell work) | <10 EU/mg | LAL assay |
| pH (1% aqueous solution) | 5.0–7.0 | pH electrode |
---
Safety Profile and Tolerability
Published Safety Data
SNAP-8's safety profile is well-characterized from cosmetic human studies and in vitro models:
- •Dermal irritation: Non-irritating under repeat insult patch test (RIPT) at 3–10% concentrations; no sensitization observed in maximization tests
- •Acute dermal toxicity: Not applicable as a cosmetic ingredient at use levels; estimated systemic exposure negligible given poor transdermal absorption
- •Genotoxicity: No genotoxic activity in Ames test or in vitro chromosomal aberration assay at relevant concentrations
- •Ophthalmological safety: Ocular irritation testing classified SNAP-8 as non-irritating to minimally irritating; suitable for periorbital formulations at ≤5%
- •Systemic absorption: Minimal transdermal penetration of intact peptide; no documented systemic effects in clinical use
Contraindications for Research Protocols
- •Avoid preparation or testing on individuals with known sensitivity to cosmetic peptide ingredients
- •Peptide-containing formulations require appropriate preservative systems for microbiological safety
- •Antioxidant protection is necessary to maintain SNAP-8 activity in formulations with shelf-life claims
---
Sourcing Guidance
Peptides.SO lists 48 suppliers carrying SNAP-8, making it one of the most accessible cosmetic peptides for research procurement. When evaluating suppliers, prioritize:
1. Certificate of Analysis (CoA): Confirm purity ≥95%, with MS confirmation of molecular weight (1,075.16 Da)
2. HPLC trace supplied: Verify single peak, no major impurities
3. Form and concentration: Lyophilized powder vs. pre-dissolved liquid; verify stated concentration
4. Lot-to-lot consistency: For longitudinal research, specify lot and request CoA per shipment
5. Regulatory documentation: For cosmetic formulation use, supplier should provide INCI name (Acetyl Octapeptide-3), safety data sheet, and compliance documentation for relevant markets (EU Cosmetics Regulation, US FDA 21 CFR)
> Browse SNAP-8 suppliers and compare listings at Peptides.SO SNAP-8 compare page.
---
Research Summary and Protocol Checklist
Standard Protocol Parameters
| Parameter | Standard Research Setting | Notes |
|---|---|---|
| Primary research form | Lyophilized powder or 10% aqueous concentrate | |
| Reconstitution solvent | Sterile water or PBS | High water solubility, simple reconstitution |
| Stock concentration | 10 mg/mL (water) | Stable at 4°C for ≥3 months |
| Working concentration (topical) | 3–10% in formulation | Most-studied range in published trials |
| Working concentration (in vitro) | 0.001–1 mg/mL | Adjust per assay; verify cell viability |
| pH of formulations | 5.5–6.5 | Optimal for peptide stability and skin compatibility |
| Storage (lyophilized) | −20°C, desiccated, dark | Stable >24 months |
| Storage (solution) | 4°C, ≤12 months | Include antioxidant; avoid freeze-thaw |
| Freeze-thaw cycles | ≤3 | Monitor by HPLC for degradation |
| Minimum purity for research | ≥95% HPLC | ≥98% for mechanistic cell studies |
Protocol Checklist Before Starting
- •[ ] Confirm SNAP-8 purity ≥95% by CoA / HPLC
- •[ ] Verify molecular weight (1,075.16 Da) by mass spectrometry on CoA
- •[ ] Reconstitute in sterile water or PBS; do not exceed 40°C
- •[ ] Confirm pH 5.5–7.0 before use
- •[ ] For cell studies: dilute to working concentration in culture-compatible solvent; confirm absence of cytotoxicity with MTT assay at experimental concentration
- •[ ] For formulation work: add peptide at ≤40°C; include antioxidant system; confirm pH of finished formulation 5.5–6.5
- •[ ] Include vehicle-only control condition in all cell-based assays
- •[ ] Store aliquots at −20°C; track freeze-thaw count
---
For the complete mechanistic background on SNAP-8's SNARE inhibition pathway, synaptic biology, and in-depth clinical data, see the SNAP-8 Complete Research Profile.
This article is for educational and research purposes only. SNAP-8 is not an FDA-approved therapeutic. All protocols described herein are derived from published scientific literature and are intended for use only by qualified researchers within approved research frameworks.